AstraZeneca PLC

AZN

74.93 (-2.12%) 1.59

232.28(B)

Health Care

Pharmaceuticals

AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Farxiga Brilinta Crestor Seloken Lokelma Roxadustat Andexxa Wainua Symbicort Fasenra Pulmicort Breztri/Trixeo Saphnelo Tezspire Airsupra Ultomiris Soliris Strensiq Koselugo Kanuma Atacand Plendil Modip Splendil Munobal Flodil Komboglyze Qtern Byetta XIGDUO Accolate Accoleit Vanticon Beyfortus Synagis FluMist tixagevimab and cilgavimab and sipavibart. It also provides Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Bricanyl Turbuhaler Rhinocort Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Breztri Aerosphere Duaklir Genuair Kavigale Evusheld Fluenz/FluMist and Voydeya. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom the United States Europe and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.

Holdings:

Cost basis:

Valuation Overview Growth Estimates Per Share Data Similar Companies Historical Data Calculators

AstraZeneca PLC (AZN) price target and intrinsic value estimate

AZN's fair price estimate is $55.7

This valuation is based on a fair P/E of 10.9 and EPS estimates of $5.13

Is AZN overvalued or undervalued?

AZN is currently trading at $74.93

AZN is overvalued by 35% using the pevaluation method.

Do you agree with this valuation?

Access thousands of companies and create your own custom market model.
Claim your FREE account

Valuation

PEvaluation

Current price

$74.9

Overvalued

Low

$41.7

Median

$55.7

High

$69.6

Fair P/E

Margin of safety

Analyst valuation

N/A
No analyst price targets

Strong Buy5

Buy12

Hold3

Sell0

Strong Sell0

Discounted cash-flow

N/A
Negative FCF or FCF estimates

TTM FCFFCF est.Growth FCFTerminal FCF

Discount
rate10%

Terminal
rate5%

Growth p.
length5y

Growth p.
rate10%

Economic moat: None/narrow

Overview

Market data

Market cap:$232.28(B)

Enterprise value:$258.15(B)

Total Equity:$40.87(B)

Shares outstanding:3.10(B)

Div. yield:2.07%

P/S:4.29

P/E:33.00

P/FCF:23.37

P/B:5.70

EPS:$2.3

FCF per share:$3.2

Dividend per share:$1.6

Income (TTM)

Revenue$54.07(B)

Gross profit$44.44(B)

EBITDA$17.57(B)

Net income$7.04(B)

Gross margin82.2%

Net margin13.0%

Balance sheet

Total assets$104.03(B)

Total liabilities$63.16(B)

Cash & Short-term inv.$5.53(B)

Long-term debt$26.62(B)

Debt issued$6.49(B)

Debt repaid$-5.00(B)

Cash flow (TTM)

FCF$9.94(B)

CapEx$-1.92(B)

Dividends paid$-4.63(B)

Stock issued$38.00(M)

Stock repurchased$-81.00(M)

Stock-based comp.$660.00(M)

Per Share Data

Zoom x1

Show Growth

Growth Estimates

Revenue

CAGR: 6.7%

FY+1$57.35(B)

FY+2$60.87(B)

FY+3$64.70(B)

FY+4$68.01(B)

FY+5$74.36(B)

Net Income

CAGR: 11.6%

FY+1$13.82(B)

FY+2$15.76(B)

FY+3$17.69(B)

FY+4$18.94(B)

FY+5$21.43(B)

EPS

CAGR: 13.1%

FY+1$4.48

FY+2$5.08

FY+3$5.71

FY+4$6.29

FY+5$7.33

FCF per share

CAGR: 10.7%

FY+1$5.06

FY+2$5.88

FY+3$6.13

FY+4$6.58

FY+5$7.61

Similar Companies

Historical Financials

Showing limited histrical data. Access 10+ years of financials now! Upgrade

YearlyQuarterly

Income

RevenueOperating IncomeNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomePre-tax incomeIncome tax

Cash flow

Stock-based Comp.FCFCFONet IncomeD&ACFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures

Balance sheet

Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity

Per share data

EPS (Basic)FCF/ShareDividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share

Ratios

P/EP/SEV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio

Margins

Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin

Returns

ROICROAROCEROE

Shares outstanding

Shares (Basic)Shares (Diluted)

Market Cap.

Calculators

Future P/E valuation

Projection Years:

Base Revenue:

Revenue Growth Rate (%):

Final Net Margin (%):

Final P/E Ratio:

Discount Rate (%):

Graham formula

Earnings Per Share (EPS):

Expected Growth Rate (%):

Government Bond Rate (%):

Dividend discount model

Annual Dividend ($):

First Stage Length (Years):

First Stage Growth Rate (%):

Second Stage Growth Rate (%):

Discount Rate (%):